Compare Inovio Pharmaceuticals Inc (INO) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Norwegian Cruise Line Holdings Ltd trades at $15.54 (market cap $7.11B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 63.4× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| INO | NCLH | |
|---|---|---|
Market Cap | $112.19M | $7.11B |
Volume | 3,201,278 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $25.02 |
52-Week Low | $0.66 | $14.12 |
Typical Hold Time | 43 Days | 68 Days |
Enterprise Value | $83.51M | $21.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
NCLH trades at $15.495, up 2.96% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding expectations, and anticipates Q3 2026 results above guidance. Valuation metrics appear attractive with a P/E of 9.39 and P/S of 0.75. Analyst consensus is a Buy with a $20.86 price target, indicating 34% upside potential. Recent news highlights strategic initiatives like earlier booking resets and new senior note offerings to manage debt.
The outlook for NCLH is positive, driven by earnings momentum and favorable analyst sentiment, but risks include persistent yield pressure and high debt levels. Investment opportunity lies in the stock's discounted valuation relative to growth prospects, though investors must monitor Caribbean pricing trends and the company's ability to sustain profitability amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
